Clinical data | |
---|---|
Trade names | Befol (RU) |
Other names | Befol |
Routes of administration | Oral |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C14H19ClN2O2 |
Molar mass | 282.77 g·mol−1 |
3D model (JSmol) | |
| |
|
Eprobemide (INN) is a pharmaceutical drug that was used as an antidepressant in Russia (under the brand name Бефол/Befol).[1] It is a non-competitive reversible inhibitor of monoamine oxidase A[2][3] that exhibits selective action on serotonin deamination.[4] Eprobemide differs from moclobemide only in the linker that connects the morpholine fragment with the chlorobenzamide — moclobemide has two carbon atoms while eprobemide has three. Its registration was cancelled on December 30, 2003.[5]